Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO II randomized, prospective, ...

Publication reports statistically significant improvement in sleep quality following treatment with Nexalin’s 15 mA, 77.5 Hz stimulation ...

Marvell Technology Inc. has acquired plasmonics-based silicon photonic device maker Polariton Technologies. The move will strengthen Marvell’s optical technology portfolio, adding advanced modulation ...

Oral presentations highlight first-in-human data for TRX103 and novel CAR-Tr1 Treg therapy TRX319. Data underscore potential ...

A rolling NDA has been initiated for tinlarebant in STGD1, potentially positioning the first disease-modifying systemic ...

Confirmed RECIST v1.1 ORR favored varegacestat (56% vs 9%; P<.0001), with exploratory median best tumor-volume change of −83% ...

Sensory processing is fundamental to perception, action, and cognition, and its disruption contributes to a wide range of neurological, psychiatric, and ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

Marvell Technology acquired Polariton Technologies in a push to develop faster connectivity technology to support artificial-intelligence workloads.

SemiTech's fair value price target has been marked slightly higher, shifting from US$104.62 to US$105.54, a move of about 0.9%. That tweak lines up with a wave of Street research that has pushed ...

CFO transition -- Abhishek Jain announced retirement, with Nathan Smith appointed as incoming CFO effective Aug. 7.

Recent breakthroughs in microscopy are enabling scientists to capture sharper, faster, and more reliable images of live cells and complex 3D samples. Caltech's Digital Defocus Aberration Interference ...